Given conflicting results regarding possible associations with cancers and the intrinsic limitations of traditional observational studies such as those introduced by confounders, our study utilized Mendelian randomization (MR) to clarify the cancer risk associated with SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is cancer.